Asset Details
Do you wish to reserve the book?
Symptom reporting and vaccination status among SARS-CoV-2-positive encounters — Increasing Community Access to Testing, Treatment, and Response program, United States, September 2023–August 2024
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Symptom reporting and vaccination status among SARS-CoV-2-positive encounters — Increasing Community Access to Testing, Treatment, and Response program, United States, September 2023–August 2024
Do you wish to request the book?
Symptom reporting and vaccination status among SARS-CoV-2-positive encounters — Increasing Community Access to Testing, Treatment, and Response program, United States, September 2023–August 2024
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Symptom reporting and vaccination status among SARS-CoV-2-positive encounters — Increasing Community Access to Testing, Treatment, and Response program, United States, September 2023–August 2024
2025
Overview
On September 12, 2023, the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices recommended that all persons aged ≥6 months receive 2023–2024 COVID-19 vaccination. This study examines the relationship between vaccination and COVID-19 symptom frequency, using data from the Increasing Community Access to Testing, Treatment, and Response (ICATT) platform. Among 6966 records of first SARS-CoV-2-positive tests collected from September 21, 2023 through August 22, 2024, individuals who received 2023–2024 COVID-19 vaccination consistently reported lower frequencies of 12 symptoms. The adjusted odds of reporting most symptoms were significantly lower among vaccinated participants, especially recent loss of sense of smell or taste (adjusted odds ratio(aOR): 0.39; 95 %CI: 0.29–0.53) and muscle pain (aOR: 0.49; 95 %CI: 0.41–0.59). These findings indicate that receiving 2023–2024 COVID-19 vaccination was associated with significantly lower odds of reporting most COVID-19 symptoms following SARS-CoV-2 infection, highlighting the importance of receiving recommended COVID-19 vaccination to mitigate symptomatic illness.
Publisher
Elsevier Ltd,Elsevier Limited
Subject
/ Adult
/ Aged
/ COVID-19
/ COVID-19 - prevention & control
/ COVID-19 Vaccines - administration & dosage
/ Editing
/ Female
/ Fever
/ Health Services Accessibility
/ Humans
/ Male
/ Pharmacy
/ Severe acute respiratory syndrome coronavirus 2
/ Symptoms
/ United States - epidemiology
/ Vaccination - statistics & numerical data
/ Vaccines
